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ABSTRACT
Vaccines are one of the greatest modern medical inventions. Even though vaccines have
saved lives, however, no medical product is proven to be completely safe. Vaccines can have
rare and sometimes deadly reactions. To address such occurrences, the U.S. Department of
Health and Human Services (HHS) hosts a program that reviews petitions for compensation of
injuries caused by vaccination. The program is called the National Vaccine Injury Compensation
Program (VICP). The VICP was established in 1986 to reduce the number of product liability
lawsuits against vaccine manufacturers that threatened to increase the cost of vaccines and lower
life-saving vaccine administration to millions of people.
In 2020, through the Health Resources and Services Administration, the HHS proposed a
revision to the VICP. Specifically, the HHS proposed removing an injury called Shoulder Injury
Related to Vaccine Administration (SIRVA) from the VICP’s no-fault compensation table.
The proposed revision of the removal of SIRVA has been the source for debate because it
is clear through the establishment of the VICP’s founding document that compensation for
injuries caused by vaccine administration is required. The HHS is challenging the requirement of
compensation for vaccine-related injuries through its proposed revision to the VICP’s
compensation table. By confronting the HHS’s proposal for revision to the Vaccine Injury Table,
this thesis demonstrates how existing policy prevents the HHS from making the revision. Using
an analysis of precedent statutes and public health research, this thesis argues for the continued
coverage of SIRVA with the current VICP.
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I. INTRODUCTION
Vaccines are one of the greatest developments of modern medicine. Since the first
Smallpox vaccine in 1796, the use of vaccines has reduced mortality rates around the world, and
in some cases eradicated diseases that were once considered deadly. Although vaccines have
been effective in protecting against deadly diseases, no medical product is proven to be
completely safe. Essential vaccines protecting against life-threatening diseases like pertussis,
tetanus, measles, rubella, and polio carry risks such as anaphylaxis, encephalitis, neuritis, and in
severe cases, death.1
Historically, people who experienced serious side effects to vaccines were forced to sue
large vaccine manufacturers for product liability or medical malpractice. Generally, suing large
vaccine manufacturers led to petitioners not being able to recover enough compensation because
they had to prove a defective product which is hard to demonstrate in court when the issue is a
negative reaction in the body. For vaccine manufacturers, in the cases where petitioners were
able to demonstrate wrongdoing, these lawsuits also threatened to drive vaccine production down
to counteract court costs. There was no cap for settlement. In addition, there was a massive
increase in the number of lawsuits. Between 1978 and 1981, only nine liability lawsuits were
recorded. In the mid-1980s, there were over 200 lawsuits.2 It created a crisis situation for both
parties.

Schwartz, V. E., & Mahshigian, L. (1987, January 1). “National childhood vaccine injury act of 1986: An ad hoc
remedy or a window for the future?.” Ohio State Law Journal,48(2), 387-398 Retrieved September 21, 2021, from
http://hdl.handle.net/1811/64373.
2
Bruesewitz v. Wyeth, 562 U.S. 223 (2011)
1
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To satisfy petitioners and vaccine companies involved in this difficult trade off, Congress
enacted the National Childhood Vaccine Injury Act of 1986 (the Act).3 The Act established the
National Vaccine Injury Program (VICP). The VICP emerged out of a national vaccination crisis
related to vaccines taken in childhood such as Diphtheria, Pertussis (Whooping Cough), Tetanus,
HPV, etc. The VICP emerged to solve the issue that both parties were facing: 1) it provided
compensation for “vaccine-related injuries or death” and 2) it shielded vaccine manufacturers
from liability.4
The threat of a reduced availability of vaccines could result in the avoidable death of
millions of people.5 The U.S. Congress acknowledged this crisis as a national public health
problem and pushed to establish a no-fault alternative to tort lawsuits.6
The no-fault alternative is VICP, often referred to as, “vaccine court.” Petitioners of the
vaccine court file a petition to be compensated for a vaccine-related injury or death. In this
petition, the petitioner must establish that they received a vaccine listed in the Vaccine Injury
Table (Table) and that they sustained an illness, disability, or injury also listed in the Table.7 The
Act defines “vaccine-related injuries or death” as an “illness, injury, condition, or death
associated with one or more of the vaccines set forth in the Vaccine Injury Table.”
One of the most prevalent injuries that occur to patients receiving vaccines by injection is
Shoulder Injury Related to Vaccine Administration (“SIRVA”). SIRVA, as the name suggests, is
a severe shoulder injury caused by faulty vaccine injection. When a vaccine is injected too

3

National Childhood Vaccine Injury Act of 1986, 42 U.S.C § 300aa-10 et seq.
42 U.S. Code § 300aa–22 – Standards of responsibility: Paragraph (b)
5
Pub. L. 99–660, title III, §311(a), Nov. 14, 1986, 100 Stat. 3756.
6
“H.R. 5546 — 99th Congress: National Childhood Vaccine Injury Act of 1986.” Retrieved from:
https://www.govtrack.us/congress/bills/99/hr5546
7
42 U.S. Code § 300aa–11
4
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deeply into the shoulder, the needle releases the vaccine contents directly into the deltoid muscle.
This can inflame the shoulder tendon and lead to excessive pain or a frozen shoulder.8 This
injury can severely impact a patient’s ability to drive, cook, or go to work. SIRVA has been
listed in the Vaccine Injury Table as an injury eligible for compensation in the vaccine court
since 2017 because scientific literature and vaccine experts have concluded that a causal link
exists between vaccine injection and the inflammation of the shoulder tendons.9
On July 20, 2020, the compensation for individuals suffering with SIRVA was put at risk.
The U.S. Department of Health and Human Services (HHS), which hosts the VICP and conducts
medical reviews of petitions, proposed a revision to the VICP to remove SIRVA from its list of
compensational injuries. HHS contends that SIRVA is related to the negligent administration of
the vaccine and not the contents of the vaccine itself.10 In their argument, the HHS alleges that
SIRVA is not “vaccine-related” because the injury is caused by improper injection. The HHS’s
attempt to exclude SIRVA because of the “administration of the vaccine” is incorrect and legally
flawed. In excluding SIRVA and other injuries related to negligent administration, the HHS calls
into question whether SIRVA should be removed from the Vaccine Injury Table.
This paper argues that SIRVA should not be removed from the Vaccine Injury Table
because as a matter of policy, amending the Table with respect to SIRVA petitioners is
inconsistent with the Act’s original language that was written by Congress. Congress states in the
Act that “No person may bring a civil action for damages in an amount greater than $1,000 or in

Shahbaz, M., Blanc, P.D., Domeracki, S. J., Guntur, S..(2019) “Shoulder Injury Related to Vaccine Administration
(SIRVA): an occupational case report.” Workplace Health Safety.67(10):501-505. doi: 10.1177/2165079919875161.
9
National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table, 80 FR 45132 (July 29,
2015)
10
National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table, 85 FR 43794 (July 20,
2020)
8
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an unspecified amount against a vaccine administrator or manufacturer in a State or Federal court
for damages arising from a vaccine-related injury or death associated with the administration of a
vaccine after the effective date of this part…”.11 Congress used the term “administration of a
vaccine” multiple times within the Act. This thesis demonstrates how the HHS’s express
disregard of the law is flawed and should not be passed.
To support this argument this thesis first reviews the language of the legislation made by
the Congress to demonstrate opposition of the revision. Additionally, this thesis shows through
evaluation of applicable statutes, case law, and other research articles that the VICP has a duty to
protect those adversely affected by life-saving vaccines, even if the adverse reaction is caused by
negligent administration. This thesis stands with SIRVA patients to continue receiving
compensation from the VICP.

11

42 U.S.C. § 300aa-11 (a)(2)
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II. BACKGROUND
Early History of the Vaccine Crisis
In the 1980s, the number of lawsuits against Diphtheria, Tetanus, and Pertussis (DTP)
vaccine manufacturers showed a dramatic increase. The DTP vaccine is lifesaving, protecting
against three diseases: diphtheria, pertussis, and tetanus. People who had adverse reactions to the
vaccination felt symptoms of fever, seizure, and encephalopathy.12
The total amount of money claimed from only half of the cases heard in 1986 was $2.5
billion.13 The staggering amount of money paid to petitioners of product liability lawsuits against
major vaccine manufacturers negatively affected the availability of life-saving vaccines on the
market. In a 1986 article written by Dr. Alan Hinman, the crisis of this situation is illustrated as
follows:
The total amount claimed in 1984 DTP vaccine suits ($1.3 billion) is more than 20 times
the total value of 1984 sales of DTP vaccine at the 1984 market price of $2.80 per dose...If the
current trend continues, suits will pose an increasing threat to the availability of DTP vaccine in
the United States.14
Product liability lawsuits thus threatened to increase the costs of vaccines and drive down
production. Fewer people had access to vaccines that could potentially save their lives as a result.
It was obvious that a change needed to be made.

Blumberg DA, Lewis K, Mink CM, Christenson PD, Chatfield P, Cherry JD. (2019). “Severe reactions associated
with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive
episodes, high fevers, and persistent crying.” Pediatrics.91(6):1158-65. PMID: 8502521.
13
Hinman, A.R. DTP Vaccine Litigation. (June 1986) Am J Dis Child.;140(6):528–530.
doi:10.1001/archpedi.1986.02140200038022
14
Ibid., 529.
12
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To effect change, Congress enacted the National Childhood Vaccine Injury Act of 1986.
The Act established a no-fault claims court in which petitioners could receive compensation for
vaccine-related injuries or death. The Act addressed two concerns: first, the number of lawsuits
against vaccine manufacturers would be greatly reduced. The Act prohibited civil actions against
vaccine administrators and manufacturers for injuries associated with the administration of a
vaccine.15 People who were injured or died due to vaccine administration could no longer sue the
manufacturer or administrator and would have to file a petition with the National Vaccine Injury
Compensation Program (VICP).
Second, the Act offered people injured by vaccines a source of repayment or
compensation for their medical needs, including rehabilitation. Essentially, people suffering from
vaccine-related injuries were mandated to petition for compensation under the VICP. They could
not sue vaccine manufacturers for repayment of issues suffered from their vaccine-related injury
and their only source for this repayment was the VICP. Therefore, the National Childhood
Vaccine Injury Act of 1986 was a solution to a national public health crisis. It created an
alternative to tort lawsuits in which plaintiffs could be overpowered by large corporations and
never receive the compensation they needed.

The VICP Process
The process of the VICP begins with filing a petition with the United States Court of
Federal Claims. Upon the initial filing, the petitioner must make clear to the Secretary of the
Department of Health and Human Services whether their injury is “vaccine-related”.
The Act of 1986 states the following:

15

42 U.S. Code § 300aa–11 (a)(3)
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A proceeding for compensation under the Program for a vaccine-related injury or death
shall be initiated by service upon the [Secretary of Health and Human Services] and the filing of
a petition containing the matter prescribed by subsection (c) with the United States Court of
Federal Claims.16
The key piece of requesting for compensation under the VICP is filing a petition which
includes an affidavit and supporting documentation. The petition should demonstrate that the
person who was injured or died had received a vaccine listed in the Vaccine Injury Table. The
Vaccine Injury Table (Table) is a list of:17
...Vaccines, the injuries, disabilities, illnesses, conditions, and deaths resulting from the
administration of such vaccines, and the time period in which the first symptom or manifestation
of onset or of the significant aggravation of such injuries, disabilities, illnesses, conditions, and
deaths is to occur after vaccine administration for purposes of receiving compensation under the
[VICP].18
Essentially, the Table is the first step that petitioners and the Secretary of the HHS take to
discover whether the claim is eligible for compensation under the VICP. Vaccines that are listed
in the Table for coverage by the VICP are: diphtheria, tetanus, pertussis (whooping cough),
measles, mumps, rubella (German measles), polio, hepatitis A, hepatitis B, varicella
(chickenpox), Hemophilus influenzae type b, rotavirus, pneumococcal conjugate, trivalent
influenza (seasonal flu), meningococcal conjugate, and human papillomavirus.19
These vaccines in the Table also have injuries and onset time periods that are eligible for
compensation. Various vaccine-related injuries, disorders, or disabilities can be applied as
reactions to multiple vaccines.

16

42 U.S. Code § 300aa–11 (a)
See Appendix A
18
42 U.S.C. 300aa-14(c)
19
Vaccine injury compensation program. The United States Department of Justice. (2018, September 24). Retrieved
October 1, 2021, from https://www.justice.gov/civil/vicp.
17
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Once a petitioner has identified the vaccine, injury, and onset time period in their
petition, it must be approved as valid by the U.S. Department of Health and Human Services
(HHS). Upon that approval, they are eligible for a hearing with the “special master” who makes
the decision for whether they receive compensation under the VICP. The VICP is funded by a
trust fund that gathers funds from an excise tax on each dose of vaccine that is purchased. The
monies from this trust fund are what is distributed for compensation.20

SIRVA: A Rare Reaction
As previously stated, a number of vaccine-related injuries can occur as a result of the
administration of various vaccines. One of these injuries, Shoulder Injury Related to Vaccine
Administration (SIRVA),can occur with any vaccine administered by injection. SIRVA is
described as a rapid occurrence of shoulder pain and dysfunction that persists as a result of
complications in the deltoid muscle.21 When most people are receiving vaccines through
injection, they experience mild, transient pain in the shoulder area.22 The pain usually does not
persist or significantly impact quality of life. In cases of people suffering with SIRVA, the injury
can be debilitating.
People who have SIRVA have ongoing work restrictions and the symptoms can last from
6 months to years. According to a case report from 2019, a total of 31% of SIRVA cases required

20

National Vaccine Injury Compensation Program. Official web site of the U.S. Health Resources &amp; Services
Administration. (2021, September 29). Retrieved October 4, 2021, from https://www.hrsa.gov/vaccinecompensation/index.html.
21
Szari, S., Belgard, A., Adams, K., & Freiler, J. (2019). “Shoulder Injury Related to Vaccine Administration: A
Rare Reaction.” Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 36(8), 380–384.
22
Cantarelli Rodrigues, Tatiane et al. “Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of
shoulder injury related to vaccine administration (SIRVA).” Skeletal Radiology vol. 50,11 (2021): 2293-2297.
doi:10.1007/s00256-021-03803-x
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surgical intervention.23 SIRVA is considered a “preventable injury”. The injury occurs as a result
of unintentional injection of vaccine or trauma from an inappropriate sized needle into the
underlying fluid sac (bursa) of the shoulder.24 SIRVA can be a severe injury to the
musculoskeletal structures of the shoulder.
An infographic25 developed by the University of Waterloo in Ontario, details how various
improper injection administration types can result in SIRVA. The infographic notes that an
injection too high up on the shoulder can result in injecting the contents of the vaccine directly
into the shoulder joint or bursa and that an injection too far to the side of the shoulder can result
in injecting the vaccine contents into the auxiliary nerve. This misadministration of the vaccine
can cause paralysis and/or neuropathy in the patient almost immediately.26 SIRVA is dangerous,
and while rare, it is a serious adverse effect to vaccine injection.
In 2017, following extensive scientific research and a report released from the Institute
of Medicine, the HHS added SIRVA to the VICP Table to be eligible for compensation upon
petition.27 As one of the known adverse events from vaccination, petitioners had to demonstrate
through medical records that: 1) they had no history of pain, inflammation, or dysfunction in the
affected shoulder prior to the vaccine administration, 2) the pain they have experience occurs
within 48 hours of the vaccine administration, 3) the pain and reduced motion only occur in the

Shahbaz, M., Blanc, P. D., Domeracki, S. J., & Guntur, S. (2019). “Shoulder Injury Related to Vaccine
Administration (SIRVA): An Occupational Case Report.”. Workplace Health & Safety, 67(10), 501–
505. https://doi.org/10.1177/2165079919875161
24
Ryan, T. (n.d.). “Updating the vaccine injury table”. Retrieved October 5, 2021, from https://akastagewww.hrsa.gov/sites/default/files/advisorycommittees/vaccines/2012/March%208-9/20120308-iomreportupdate.pdf.
25
See Appendix B
26
Bancsi, A., et al. (2019) “Shoulder injury related to vaccine administration and other injection site events.”
Canadian Family Physician vol. 65,1, 40-42.
27
85 FR 43794
23
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shoulder that the vaccine was injected in, and 4) the petitioner has no other condition that would
explain the symptoms they experienced.28
It is significant to report that 93% of VICP petitioners reported showing symptoms within
48 hours of vaccination. These petitioners also reported having persistent symptoms that lasted
longer than a few weeks.29 When people petition a case to the VICP to report that they have
SIRVA, they are reporting because they are aware that their persistent shoulder pain and
dysfunction can have a severe impact on their ability to work, exercise, and participate fully in
their daily life.

28

Ibid. 17
Clinic, C. (2021, September 24). “SIRVA Reprise, COVID Vaccine Injury Fund.” Retrieved October 5, 2021,
from https://www.carilionclinic.org/news/417---sirva-reprise-covid-vaccine-injury-fund/.
29
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III.

DISCUSSION

SIRVA can have a serious effect on the livelihood of people. The injury can be so serious
that the costs of medicine and rehabilitation overwhelms patients. Prior to being added to the
VICP, the compensation received by SIRVA patients from 2011 to 2016 was $29,087,666.30 The
compensation awarded by the Special Master is capped at $250,000 and pays for a large sum of
medical and rehabilitative bills from their vaccine-related injury. The Act was created for the
purpose of providing an easier and cheaper alternative to civil litigation for individuals who
suffered injuries caused by the administration of vaccines.
When petitioners claim SIRVA as a result of the administration of a vaccine they are able
to receive compensation for their medical and rehabilitative bills. They are only able to receive
compensation because SIRVA and the vaccine they received is listed on the Vaccine Injury
Table (Table). Even though people who suffer from SIRVA can be out of work for months and
are reliant on compensation from the VICP, the Department of Health and Human Services
(HHS) petitioned on July 20th, 2020 to remove SIRVA from the Vaccine Injury Table.31 The
HHS is the administrative body of the VICP and proposes changes to the Vaccine Injury Table
when they receive new scientific knowledge about vaccines, injuries, disorders, etc. The Health
Resources and Service Administration regulates discussion of these petitions by the public.
Should the HHS remove SIRVA from coverage under the VICP? Upon majority
disagreement with the HHS’s petition to remove SIRVA from the VICP’s Vaccine Injury Table,
the HHS rescinded their proposal in April of 2021. This thesis demonstrates why the HHS should

30

Update on SIRVA, HHS.gov. (n.d.). Retrieved November 8, 2021, from
https://www.hhs.gov/sites/default/files/Nair_Special%20Highlight_SIRVA%20remediated.pdf.
31
42 CFR Part 100, Federal Register / Vol. 85, No. 139 / Monday, July 20, 2020
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not resuscitate the proposal by reviewing prior case law and interpreting the language of
established regulations, penal code, and opinions of the courts.

Defeated Purpose Of The Act
The purpose of the National Childhood Vaccine Injury Act was to significantly
reduce the amount of people who file strict liability lawsuits against vaccine manufacturers in
civil court and compensate those who took on the risk of vaccination and suffered a vaccinerelated injury or death as a result. The risk of adverse reaction to vaccination is taking on by the
majority of people because vaccines are necessary to keep us safe from life-threatening diseases.
SIRVA is one of these adverse risks.
By removing SIRVA from the Vaccine Injury Table, the HHS is defeating the original
purpose of the Act. As explained in the original language of the Act:
The Secretary shall establish in the Department of Health and Human Services, a
National Vaccine Program to achieve optimal prevention of human infectious diseases through
immunization and to achieve optimal prevention against adverse reactions to vaccines.32
The Act’s core purpose is to prevent spread of infectious diseases through encouraged
immunization and prevent adverse reactions to vaccines. Needless to say, adverse reactions to
vaccines are, for the most part, unavoidable. SIRVA is preventable through proper education and
training of healthcare personnel; however, injuries still happen and the people that suffer from
SIRVA should be compensated. The Act encourages immunization by offering the VICP.
The government’s responsibility is to ensure that systems are in place to encourage
vaccination or prevent the spread of human infectious diseases. The most common method for

32

100 STAT. 3756 PUBLIC LAW. SEC. 2101.
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governments to protect those who are “damaged” by compulsory or recommended vaccines. By
offering this method of compensation, vaccine hesitancy declines, and the spread of disease is
reduced.33Governments weigh the costs of spending billions to compensate those who bore the
risk of being adversely affected by a recommended vaccine alongside the cost of increased
percentages of vaccine hesitancy, reduced rates of vaccination, and increased spread of
preventable infectious diseases.
With removal of SIRVA from the Vaccine Injury Table, the HHS runs the risk of
decreasing public confidence in vaccines that prevent preventable diseases. According to Parmet
(2010), a leading expert on public health law, in her article “Pandemic Vaccines-The Legal
Landscape”, highly publicized lawsuits against vaccine manufacturers run the risk of
undermining confidence in vaccines.34 If the HHS removes SIRVA from the VICP, petitioners
may attempt to sue vaccine manufacturers in traditional court. In addition to running the risk of
decreasing confidence in vaccines, the HHS can lose valuable information about SIRVA patients
that may be useful in the future. The VICP allows for the United States to identify and research
the causes of the vaccine-related injuries that may go otherwise unnoticed (due to its rare nature).
For SIRVA especially, claims within the VICP has allowed for research to explore vaccine
delivery technologies that avoid improper injections.35 The research being done can eradicate
SIRVA completely by educating vaccine administrators and healthcare providers on the proper

D’Errico, S.; Zanon, M.; Concato, M.; Peruch, M.; Scopetti, M.; Frati, P.; Fineschi, V.(2021). ““First Do No
Harm”. No-Fault Compensation Program for COVID-19 Vaccines as Feasibility and Wisdom of a Policy Instrument
to Mitigate Vaccine Hesitancy.” Vaccines, 9, 1116. https://doi.org/10.3390/vaccines9101116
34
Parmet, W. E., (1970, November 11). “Pandemic vaccines - the legal landscape.” New England Journal of
Medicine. Retrieved November 12, 2021, from https://www.nejm.org/doi/full/10.1056/NEJMp1000938.
35
Ibid. 1242.
33

13

vaccine injection practices. However, if SIRVA is removed from the VICP then the resources
and attention necessary to eradicate SIRVA may never be provided.
The removal of SIRVA from the Table would cause people who suffer from SIRVA to
sue vaccine administrators for negligence and liability. Without compensation from the VICP,
SIRVA patients are forced to find other resources to pay for medical and rehabilitative costs. An
increase in the number of lawsuits against vaccine administrators could be a disincentive to
vaccine administration and has potential to lead to a vaccine crisis where vaccine administrators
are overwhelmed by lawsuits. The proposal to remove SIRVA completely disregards the
purposes of the Act.

The HHS’ Proposed Rule
The HHS’ primary argument for the removal of SIRVA was that the injury is preventable
and caused by negligent injection of vaccines. Their basis for this argument is that SIRVA is
often caused by an inappropriate sized needle or poor injection technique; it is not caused by the
antigens of the vaccine. 36
Stephen Sugarman, a professor of torts at UC Berkeley School of Law, explores the
results that can occur when an injury is not listed on the Table. In his article, Sugarman shares
that a committee of advisors works to amend the Table to add new injuries as “the consensus
view changes with the availability of new studies.”37 SIRVA has been part of the Table since
2017 and it has been proven that there is a scientific causal link between vaccine injection and
the injury. HHS’s proposed revision is not based on new studies demonstrating a lack of

36

85 FR 43794
Sugarman, S. (2007). “Cases in vaccine court — legal battles over vaccines and autism”. The New England
Journal of Medicine, 357, 1275-1277. DOI: 10.1056/NEJMp078168
37
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connection between vaccine injection and the shoulder injury instead, the revision is based on a
misreading of the legislation and misrepresentation of the existing statutes.
In a 1993 federal claims case, the Court found that when the patient’s injury was a result
of negligent administration of the vaccine, they had no difficulty in concluding that any resulting
injury from the vaccine is vaccine-related.38 Since an injury that occurs as a result of negligent
administration is still considered vaccine-related, the HHS cannot remove SIRVA from the
Table.
SIRVA is a vaccine-related injury and therefore, should continue to be compensated for
through the VICP. Recent cases of SIRVA petitioners have shown that the Courts agree. A case
heard in 2021, a petitioner alleged that they had developed SIRVA after a recent vaccine
administration.39 The plaintiff proved that the vaccine caused them to suffer from SIRVA for
more than 6 months after the initial vaccination. The Courts established that:
the Table Injury is presumed to have been caused by the vaccination, and the petitioner is
automatically entitled to compensation, unless it is affirmatively shown by the government that
the injury was caused by some other factor other than the vaccination.40
The “but-for” clause prevents the HHS from removing SIRVA from the Table because
petitioners are already required to meet the prongs of SIRVA to demonstrate that “but-for” the
administration of the vaccine they would not have sustained their injuries.41 If the government
cannot demonstrate that the injury sustained had no causal relationship with the vaccine then the
VICP must compensate the petitioner.
38

Amendola v. Sec'y, HHS, 989 F.2d 1180, 1181 (Fed. Cir. 1993)
Yost v. Sec'y of HHS, , at *9, Fed. Cl. May 6, 2021
40
Yost v. Sec'y of HHS, Fed. Cl., May 6, 2021
41
86 FR 21209
39
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While acknowledging the definition of SIRVA and reasoning provided by the HHS, the
HHS’s proposed rule must be rescinded because no medical evidence or statutory evidence has
been found that SIRVA is not causally related to vaccination. Moreover, removal of SIRVA
poses serious risk to public health. The removal of SIRVA from the VICP’s Vaccine Injury
Table may cause a decline in vaccine administration, an increase in vaccine hesitancy, and a
spread of preventable infectious diseases.

16

IV.

CONCLUSION

The purpose of the Act of 1986 was to “ensure the production and procurement of safe
and effective vaccines” and “direct the distribution and use of vaccines.” By creating the NVICP,
Congress effectively met those prongs by allowing those injured by vaccine injection to use an
alternative remedy to receive compensation for their injuries. This compensation program
increases the likelihood of people taking on the risk of vaccination. Yet, despite this central
purpose of the Act, the HHS is proposing to remove SIRVA from the Vaccine Injury Table.
SIRVA should not be removed from the Table because the principle of the Act is to
protect community members by offering a no-fault remedy to compensate them. By recognizing
the history of the Act of 1986 and the purpose of the vaccine court, this thesis has shown that the
HHS must keep SIRVA on the Table. Although the HHS has defined coverage on the Table,
removal of SIRVA is ill-advised. SIRVA is one of the potential adverse effects of vaccine
injection. Similar to other vaccine-related injuries, such as arthritis or brachial neuritis, SIRVA
can be debilitating for patients, and they may never fully recover.
SIRVA’s removal from the Table may have harmful effects on the vaccine administration
process. In a climate where anti-vaccination sentiments have increased, removing one of the
most prevalent injuries from the compensation table seems counterproductive and inappropriate.
People that suffer SIRVA symptoms have reported that a loss of feeling in their shoulder, have to
endure extensive surgery, rehabilitative sessions, and are unable to work. Previously, the
compensation offered by the VICP made people more comfortable with undertaking the risk of
injury with vaccine injection.
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The no-fault coverage of victims who suffer from SIRVA should continue. They should
remain on the list of those who receive compensation for taking on adverse risks. Facing adverse
risk by receiving vaccines is part of community members’ responsibility to keep the entire
community safe. Getting vaccinated is part of community duty and people take on that risk so
that they can protect those in the community who are physically incapable of vaccination.
SIRVA, as one of the most prevalent cases filed in vaccine court, should remain on the
Injury Table because our government’s duty is to protect the interests of society.42 Part of that
duty is to award compensation to those affected negatively by vaccine administration to
encourage vaccination amongst the wider population further. The risk of reduced vaccination
rates far outweighs the HHS’s call to follow the technicality of definition.
At this time, COVID-19 vaccines are not covered in the Vaccine Injury Table and
therefore won’t be impacted by the proposed rule to remove SIRVA. However, COVID-19
vaccines may be added to the Vaccine Injury Table in the future and as we learn more about the
effects of the vaccine, we may see SIRVA as an adverse reaction. The proposal to remove
SIRVA from the VICP is untimely when anti-vaccination sentiments are rising across the
country. With the potential of compensation, SIRVA remaining on the Vaccine Injury Table can
give people the confidence to vaccinate themselves.
The HHS’s proposal for revision to the Vaccine Injury Table has been challenged and
evidence has shown a lack of statutory support for removing SIRVA from the Table. Scientific
research has shown that SIRVA originates from negligent vaccine administration. And yet, the

Seiler, N., Taylor, H., Faden, R., (2004) “Legal and Ethical Considerations in Government Compensation Plans:
A Case Study of Smallpox Immunization”, 1 Ind. Health L. Rev. 1. Retrieved from
https://mckinneylaw.iu.edu/ihlr/pdf/vol1p1.pdf
42
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definition of SIRVA does not exclude the injury from coverage under the VICP. Compensation
under the VICP is important to our vaccination system in the United States. The HHS should not
be allowed to remove a prominent injury from the VICP without providing scientific evidence or
statutory support for its proposal.

19

APPENDIX A
Vaccine Injury Table
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42 U.S.C. 300aa-14(c)
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APPENDIX B
SIRVA and other injection site events.

Bancsi A, Houle SKD, Grindrod KA. Shoulder injury related to vaccine administration and other injection site events. Can Fam
Physician. 2019 Jan;65(1):40-42.
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